

Anthera pharma - What More After VISTA-16 Failure?

<https://marketpublishers.com/r/A658BAEAFB3EN.html>

Date: March 2012

Pages: 2

Price: US\$ 90.00 (Single User License)

ID: A658BAEAFB3EN

Abstracts

Discontinuation of VISTA-16 due to lack of efficacy is a big blow for Anthera Pharma (ANTH); though the PhII data of its key drug Varespladib (formerly A-002, PhIII, Acute Coronary Syndrome-ACS, unpartnered) vs. competitor GSK/HGSI's Darapladib (lipoprotein-associated phospholipase A2 inhibitor, Lp-PLA2) was promising. ANTH announced positive interim data from its PhIIb trial – PEARL-SC of Blisibimod (formerly A-623, SC PhIIb, Lupus, a selective peptibody antagonist of BLyS/BAFF), showing statistically significant reduction of B-cells with its monthly and weekly SC dosing however, under the current competitive scenario, the advantages of Blisibimod vs. Benlysta are not very compelling dimming its chances of partnership or commercial potential.

Contents

COMPANIES MENTIONED

Anthera pharma

I would like to order

Product name: Anthera pharma - What More After VISTA-16 Failure?

Product link: <https://marketpublishers.com/r/A658BAEAFB3EN.html>

Price: US\$ 90.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A658BAEAFB3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970